U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C32H45N3O4S
Molecular Weight 567.782
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NELFINAVIR

SMILES

[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC3=CC=CC=C3)NC(=O)C4=C(C)C(O)=CC=C4)[C@@H](C2)C(=O)NC(C)(C)C

InChI

InChIKey=QAGYKUNXZHXKMR-HKWSIXNMSA-N
InChI=1S/C32H45N3O4S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39)/t22-,23+,26-,27-,29+/m0/s1

HIDE SMILES / InChI

Molecular Formula C32H45N3O4S
Molecular Weight 567.782
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020778s035,020779s056,021503s017lbl.pdf

Nelfinavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Nelfinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. Nelfinavir is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir is marketed under the brand name Viracept.

CNS Activity

Curator's Comment: Nelfinavir has poor penetration into the macaque's brain and CSF, and P-gp inhibition at the BBB by zosuquidar enhanced the distribution of nelfinavir into the brain by 146-fold.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
12.0 nM [IC50]
100.0 µM [IC50]
7.3 µM [IC50]
5.1 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
VIRACEPT

Approved Use

VIRACEPT in combination with other antiretroviral agents is indicated for the treatment of HIV infection.

Launch Date

1997
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
4.7 mg/L
1250 mg 2 times / day steady-state, oral
dose: 1250 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
NELFINAVIR MESYLATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
3 mg/L
750 mg 3 times / day multiple, oral
dose: 750 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
NELFINAVIR MESYLATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
4 mg/L
1250 mg 2 times / day multiple, oral
dose: 1250 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
NELFINAVIR MESYLATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
35.3 mg × h/L
1250 mg 2 times / day steady-state, oral
dose: 1250 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
NELFINAVIR MESYLATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
43.6 mg × h/L
750 mg 3 times / day multiple, oral
dose: 750 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
NELFINAVIR MESYLATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
52.8 mg × h/L
1250 mg 2 times / day multiple, oral
dose: 1250 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
NELFINAVIR MESYLATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.8 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NELFINAVIR MESYLATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
3.4 h
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NELFINAVIR MESYLATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
2%
unknown, unknown
NELFINAVIR MESYLATE serum
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1250 mg 2 times / day steady, oral
MTD
Dose: 1250 mg, 2 times / day
Route: oral
Route: steady
Dose: 1250 mg, 2 times / day
Sources:
unhealthy, 52 years (range: 25-77 years)
n = 15
Health Status: unhealthy
Condition: Adenoid Cystic Carcinoma
Age Group: 52 years (range: 25-77 years)
Sex: M+F
Population Size: 15
Sources:
Disc. AE: Hyponatremia, Thrombocytopenia...
AEs leading to
discontinuation/dose reduction:
Hyponatremia (grade 4, 1 patient)
Thrombocytopenia (grade 3, 1 patient)
Dizziness (grade 3, 1 patient)
Elevated liver enzymes (grade 3, 2 patients)
Sources:
1250 mg 2 times / day steady, oral
MTD
Dose: 1250 mg, 2 times / day
Route: oral
Route: steady
Dose: 1250 mg, 2 times / day
Sources:
unhealthy, 59 years (range: 54–75 years)
n = 8
Health Status: unhealthy
Condition: Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer
Age Group: 59 years (range: 54–75 years)
Sex: M+F
Population Size: 8
Sources:
Disc. AE: Esophagitis, Nausea...
Other AEs: Leukopenia, Thrombocytopenia...
AEs leading to
discontinuation/dose reduction:
Esophagitis (grade 3, 1 patient)
Nausea (grade 3, 1 patient)
Fatigue (grade 3, 1 patient)
Other AEs:
Leukopenia (grade 3, 2 patients)
Thrombocytopenia (grade 3, 2 patients)
Dyspnea (grade 3, 1 patient)
Sources:
650 mg 2 times / day steady, oral
Dose: 650 mg, 2 times / day
Route: oral
Route: steady
Dose: 650 mg, 2 times / day
Sources:
unhealthy, 59 years (range: 54–75 years)
n = 5
Health Status: unhealthy
Condition: Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer
Age Group: 59 years (range: 54–75 years)
Sex: M+F
Population Size: 5
Sources:
Other AEs: Thrombocytopenia...
Other AEs:
Thrombocytopenia (grade 4, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Dizziness grade 3, 1 patient
Disc. AE
1250 mg 2 times / day steady, oral
MTD
Dose: 1250 mg, 2 times / day
Route: oral
Route: steady
Dose: 1250 mg, 2 times / day
Sources:
unhealthy, 52 years (range: 25-77 years)
n = 15
Health Status: unhealthy
Condition: Adenoid Cystic Carcinoma
Age Group: 52 years (range: 25-77 years)
Sex: M+F
Population Size: 15
Sources:
Thrombocytopenia grade 3, 1 patient
Disc. AE
1250 mg 2 times / day steady, oral
MTD
Dose: 1250 mg, 2 times / day
Route: oral
Route: steady
Dose: 1250 mg, 2 times / day
Sources:
unhealthy, 52 years (range: 25-77 years)
n = 15
Health Status: unhealthy
Condition: Adenoid Cystic Carcinoma
Age Group: 52 years (range: 25-77 years)
Sex: M+F
Population Size: 15
Sources:
Elevated liver enzymes grade 3, 2 patients
Disc. AE
1250 mg 2 times / day steady, oral
MTD
Dose: 1250 mg, 2 times / day
Route: oral
Route: steady
Dose: 1250 mg, 2 times / day
Sources:
unhealthy, 52 years (range: 25-77 years)
n = 15
Health Status: unhealthy
Condition: Adenoid Cystic Carcinoma
Age Group: 52 years (range: 25-77 years)
Sex: M+F
Population Size: 15
Sources:
Hyponatremia grade 4, 1 patient
Disc. AE
1250 mg 2 times / day steady, oral
MTD
Dose: 1250 mg, 2 times / day
Route: oral
Route: steady
Dose: 1250 mg, 2 times / day
Sources:
unhealthy, 52 years (range: 25-77 years)
n = 15
Health Status: unhealthy
Condition: Adenoid Cystic Carcinoma
Age Group: 52 years (range: 25-77 years)
Sex: M+F
Population Size: 15
Sources:
Dyspnea grade 3, 1 patient
1250 mg 2 times / day steady, oral
MTD
Dose: 1250 mg, 2 times / day
Route: oral
Route: steady
Dose: 1250 mg, 2 times / day
Sources:
unhealthy, 59 years (range: 54–75 years)
n = 8
Health Status: unhealthy
Condition: Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer
Age Group: 59 years (range: 54–75 years)
Sex: M+F
Population Size: 8
Sources:
Esophagitis grade 3, 1 patient
Disc. AE
1250 mg 2 times / day steady, oral
MTD
Dose: 1250 mg, 2 times / day
Route: oral
Route: steady
Dose: 1250 mg, 2 times / day
Sources:
unhealthy, 59 years (range: 54–75 years)
n = 8
Health Status: unhealthy
Condition: Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer
Age Group: 59 years (range: 54–75 years)
Sex: M+F
Population Size: 8
Sources:
Fatigue grade 3, 1 patient
Disc. AE
1250 mg 2 times / day steady, oral
MTD
Dose: 1250 mg, 2 times / day
Route: oral
Route: steady
Dose: 1250 mg, 2 times / day
Sources:
unhealthy, 59 years (range: 54–75 years)
n = 8
Health Status: unhealthy
Condition: Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer
Age Group: 59 years (range: 54–75 years)
Sex: M+F
Population Size: 8
Sources:
Nausea grade 3, 1 patient
Disc. AE
1250 mg 2 times / day steady, oral
MTD
Dose: 1250 mg, 2 times / day
Route: oral
Route: steady
Dose: 1250 mg, 2 times / day
Sources:
unhealthy, 59 years (range: 54–75 years)
n = 8
Health Status: unhealthy
Condition: Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer
Age Group: 59 years (range: 54–75 years)
Sex: M+F
Population Size: 8
Sources:
Leukopenia grade 3, 2 patients
1250 mg 2 times / day steady, oral
MTD
Dose: 1250 mg, 2 times / day
Route: oral
Route: steady
Dose: 1250 mg, 2 times / day
Sources:
unhealthy, 59 years (range: 54–75 years)
n = 8
Health Status: unhealthy
Condition: Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer
Age Group: 59 years (range: 54–75 years)
Sex: M+F
Population Size: 8
Sources:
Thrombocytopenia grade 3, 2 patients
1250 mg 2 times / day steady, oral
MTD
Dose: 1250 mg, 2 times / day
Route: oral
Route: steady
Dose: 1250 mg, 2 times / day
Sources:
unhealthy, 59 years (range: 54–75 years)
n = 8
Health Status: unhealthy
Condition: Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer
Age Group: 59 years (range: 54–75 years)
Sex: M+F
Population Size: 8
Sources:
Thrombocytopenia grade 4, 1 patient
650 mg 2 times / day steady, oral
Dose: 650 mg, 2 times / day
Route: oral
Route: steady
Dose: 650 mg, 2 times / day
Sources:
unhealthy, 59 years (range: 54–75 years)
n = 5
Health Status: unhealthy
Condition: Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer
Age Group: 59 years (range: 54–75 years)
Sex: M+F
Population Size: 5
Sources:
PubMed

PubMed

TitleDatePubMed
Non-active site changes elicit broad-based cross-resistance of the HIV-1 protease to inhibitors.
1999 Aug 20
Unexplained thrombosis in HIV-infected patients receiving protease inhibitors: report of seven cases.
1999 Dec
A generalized seizure following initiation of nelfinavir in a patient with human immunodeficiency virus type 1 infection, suspected due to interaction between nelfinavir and phenytoin.
1999 Mar
Viracept and irregular heartbeat warning.
1999 Oct
Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins.
2000 Dec
A randomized, comparative study of lamivudine plus stavudine, with indinavir or nelfinavir, in treatment-experienced HIV-infected patients.
2000 Jan 28
Anti-toxoplasma activities of antiretroviral drugs and interactions with pyrimethamine and sulfadiazine in vitro.
2000 Sep
Saquinavir soft gelatin capsule: a comparative safety review.
2001
Gynecomastia associated with highly active antiretroviral therapy.
2001 Apr
Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities.
2001 Apr
Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography--mass spectrometry assay.
2001 Aug
Antiviral drugs: current state of the art.
2001 Aug
Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens.
2001 Aug 1
HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART.
2001 Aug 1
Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss.
2001 Aug 15
Antiretroviral therapy for previously treated patients.
2001 Aug 9
Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.
2001 Aug 9
Pharmacology and clinical experience with saquinavir.
2001 Feb
Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease gene.
2001 Feb 10
Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
2001 Jan 20
Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre.
2001 Jan 26
The ADAM study continued: maintenance therapy after 50 weeks of induction therapy.
2001 Jan 5
Eruptive cheilitis: a new adverse effect in reactive HIV-positive patients subjected to high activity antiretroviral therapy (HAART). Presentation of six clinical cases.
2001 Jan-Feb
Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infection.
2001 Jul
The effects of antiretroviral protease inhibitors on serum lipid levels in HIV-infected patients.
2001 Jun
Design and synthesis of a conformationally restricted trans peptide isostere based on the bioactive conformations of saquinavir and nelfinavir.
2001 Jun 1
Hypercholesterolemia in a health care worker receiving thyroxine after postexposure prophylaxis for human immunodeficiency virus infection.
2001 Jun 1
Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography.
2001 Jun 15
The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design.
2001 Jun 15
Ergotism related to interaction between nelfinavir and ergotamine.
2001 May
Nelfinavir desensitization.
2001 May
Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors.
2001 May
P1/P1' modified HIV protease inhibitors as tools in two new sensitive surface plasmon resonance biosensor screening assays.
2001 May
Tolerability of postexposure prophylaxis with zidovudine, lamivudine, and nelfinavir for human immunodeficiency virus infection.
2001 May 15
Low incidence of genotypic and phenotypic resistance in paediatric HIV-infected patients on long-term first-line antiretroviral triple therapy.
2001 May 25
Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment.
2001 May 25
Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients.
2001 May 25
Patents

Sample Use Guides

The recommended dose is 1250 mg (five 250 mg tablets or two 625 mg tablets) twice daily or 750 mg (three 250 mg tablets) three times daily. VIRACEPT should be taken with a meal. Patients unable to swallow the 250 or 625 mg tablets may dissolve the tablets in a small amount of water. Once dissolved, patients should mix the cloudy liquid well, and consume it immediately.
Route of Administration: Oral
Nelfinavir inhibited intracellular proteasome activity in situ at drug concentrations <40 uM in human primary myeloma cells.
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:26:02 GMT 2023
Edited
by admin
on Sat Dec 16 16:26:02 GMT 2023
Record UNII
HO3OGH5D7I
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NELFINAVIR
EMA EPAR   INN   MI   VANDF   WHO-DD  
INN  
Official Name English
NELFINAVIR [EMA EPAR]
Common Name English
nelfinavir [INN]
Common Name English
Nelfinavir [WHO-DD]
Common Name English
NELFINAVIR [MI]
Common Name English
NSC-747167
Code English
NELFINAVIR [VANDF]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 554316
Created by admin on Sat Dec 16 16:26:03 GMT 2023 , Edited by admin on Sat Dec 16 16:26:03 GMT 2023
NDF-RT N0000175889
Created by admin on Sat Dec 16 16:26:03 GMT 2023 , Edited by admin on Sat Dec 16 16:26:03 GMT 2023
WHO-ATC J05AE04
Created by admin on Sat Dec 16 16:26:03 GMT 2023 , Edited by admin on Sat Dec 16 16:26:03 GMT 2023
NCI_THESAURUS C97366
Created by admin on Sat Dec 16 16:26:03 GMT 2023 , Edited by admin on Sat Dec 16 16:26:03 GMT 2023
WHO-VATC QJ05AE04
Created by admin on Sat Dec 16 16:26:03 GMT 2023 , Edited by admin on Sat Dec 16 16:26:03 GMT 2023
LIVERTOX NBK548311
Created by admin on Sat Dec 16 16:26:03 GMT 2023 , Edited by admin on Sat Dec 16 16:26:03 GMT 2023
NDF-RT N0000000246
Created by admin on Sat Dec 16 16:26:03 GMT 2023 , Edited by admin on Sat Dec 16 16:26:03 GMT 2023
Code System Code Type Description
EVMPD
SUB09186MIG
Created by admin on Sat Dec 16 16:26:03 GMT 2023 , Edited by admin on Sat Dec 16 16:26:03 GMT 2023
PRIMARY
PUBCHEM
64143
Created by admin on Sat Dec 16 16:26:03 GMT 2023 , Edited by admin on Sat Dec 16 16:26:03 GMT 2023
PRIMARY
CAS
159989-64-7
Created by admin on Sat Dec 16 16:26:03 GMT 2023 , Edited by admin on Sat Dec 16 16:26:03 GMT 2023
PRIMARY
FDA UNII
HO3OGH5D7I
Created by admin on Sat Dec 16 16:26:03 GMT 2023 , Edited by admin on Sat Dec 16 16:26:03 GMT 2023
PRIMARY
MERCK INDEX
m7798
Created by admin on Sat Dec 16 16:26:03 GMT 2023 , Edited by admin on Sat Dec 16 16:26:03 GMT 2023
PRIMARY Merck Index
SMS_ID
100000085450
Created by admin on Sat Dec 16 16:26:03 GMT 2023 , Edited by admin on Sat Dec 16 16:26:03 GMT 2023
PRIMARY
LACTMED
Nelfinavir
Created by admin on Sat Dec 16 16:26:03 GMT 2023 , Edited by admin on Sat Dec 16 16:26:03 GMT 2023
PRIMARY
MESH
D019888
Created by admin on Sat Dec 16 16:26:03 GMT 2023 , Edited by admin on Sat Dec 16 16:26:03 GMT 2023
PRIMARY
WIKIPEDIA
NELFINAVIR
Created by admin on Sat Dec 16 16:26:03 GMT 2023 , Edited by admin on Sat Dec 16 16:26:03 GMT 2023
PRIMARY
DAILYMED
HO3OGH5D7I
Created by admin on Sat Dec 16 16:26:03 GMT 2023 , Edited by admin on Sat Dec 16 16:26:03 GMT 2023
PRIMARY
NCI_THESAURUS
C29285
Created by admin on Sat Dec 16 16:26:03 GMT 2023 , Edited by admin on Sat Dec 16 16:26:03 GMT 2023
PRIMARY
NSC
747167
Created by admin on Sat Dec 16 16:26:03 GMT 2023 , Edited by admin on Sat Dec 16 16:26:03 GMT 2023
PRIMARY
RXCUI
134527
Created by admin on Sat Dec 16 16:26:03 GMT 2023 , Edited by admin on Sat Dec 16 16:26:03 GMT 2023
PRIMARY RxNorm
DRUG CENTRAL
1893
Created by admin on Sat Dec 16 16:26:03 GMT 2023 , Edited by admin on Sat Dec 16 16:26:03 GMT 2023
PRIMARY
CHEBI
7496
Created by admin on Sat Dec 16 16:26:03 GMT 2023 , Edited by admin on Sat Dec 16 16:26:03 GMT 2023
PRIMARY
ChEMBL
CHEMBL584
Created by admin on Sat Dec 16 16:26:03 GMT 2023 , Edited by admin on Sat Dec 16 16:26:03 GMT 2023
PRIMARY
DRUG BANK
DB00220
Created by admin on Sat Dec 16 16:26:03 GMT 2023 , Edited by admin on Sat Dec 16 16:26:03 GMT 2023
PRIMARY
EPA CompTox
DTXSID5035080
Created by admin on Sat Dec 16 16:26:03 GMT 2023 , Edited by admin on Sat Dec 16 16:26:03 GMT 2023
PRIMARY
INN
7494
Created by admin on Sat Dec 16 16:26:03 GMT 2023 , Edited by admin on Sat Dec 16 16:26:03 GMT 2023
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
TRANSPORTER -> SUBSTRATE
SALT/SOLVATE -> PARENT
BINDER->LIGAND
BINDING
BINDER->LIGAND
BINDING
EXCRETED UNCHANGED
FECAL
TARGET ORGANISM->INHIBITOR
Other
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
EXCRETED UNCHANGED
Only 1-2% of the dose was recovered in urine, of which unchanged nelfinavir was the major component.
URINE
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC